Approximately 8% and 18% of CLL patients requiring frontline therapy harbor defects of TP53 or ATM, respectively.3, 6 These frequencies increase when the disease progresses following initial therapies. This evidence concerns the gene ATM and B-cell chronic lymphocytic leukemia.